Bristol-Myers Squibb Foundation marks World AIDS Day with grants totaling more than $3.5M

Bristol-Myers SquibbTo mark World AIDS Day, the Bristol-Myers Squibb Foundation today announced 16 grants totaling $3.5 million for programs in Africa that strengthen HIV services for adolescents and the elderly, raise awareness and access to health care for women co-diagnosed with HIV and breast or cervical cancer, and build community capacity and integrate treatment for HIV/tuberculosis (TB) co-infection.

The grants, both new and extensions for ongoing programs, were awarded through the Foundation’s landmark Secure the Future® initiative, which brings community-based care and support to people with living with HIV in sub-Saharan Africa. Since its launch in 1999, Secure the Future has awarded more than $183 million in grants to more than 350 projects.

"The Bristol-Myers Squibb Foundation joins with our existing and new partners to continue working toward a world that is free of HIV," says John Damonti, president, Bristol-Myers Squibb Foundation. "Through these grants, the Foundation and its partners are helping to ensure that HIV-positive youth and the elderly in Africa continue to receive much-needed care and support, and that women who are co-infected with HIV and cervical or breast cancer have information and access to potentially lifesaving screening and treatment. In addition, given the close correlation between HIV infection and TB, it is essential that we work with our partners to continue strengthening community programs and approaches that integrate both diseases."

Adolescents and the elderly
Adolescents in Africa often have difficulty accessing treatment for HIV and other health and psychosocial services. In addition, stigma and other barriers result in many youth being lost to care even before beginning treatment or immediately after testing positive for HIV.

Africa also has a growing population of elderly people who are HIV-positive as a result of greater access to antiretroviral therapies and a general increase in the aging population. This trend has implications for policy, planning and practice. Most research and data have focused on the effects of the epidemic on children, youth and prime-age adults, but there is a need for studies that investigate patients 50 and older.

Grants for programs that address care and support of adolescents living with HIV will be implemented by Children’s Radio Project, South Africa; Sinomlando Project, South Africa; and AfricAid Zvandiri, Zimbabwe. Studies of HIV prevention practices among adults 50 and older and HIV/cancer co-infection among the elderly will be implemented by the University of Cape Town’s Institute of Ageing in Africa and Catholic University of Health and Allied Sciences, Tanzania.

HIV and Female Cancers
In sub-Saharan Africa, cervical and breast cancers are the leading causes of cancer death among women. The rate of cervical cancer among women living with HIV is three times higher than those who are not HIV-positive, primarily because of co-infection with the human papillomavirus (HPV), which causes cervical and other gynecological cancers. An estimated 60% to 80% of women in sub-Saharan Africa who are living with HIV are infected with HPV. The Bristol-Myers Squibb Foundation and Pink Ribbon Red Ribbon (PRRR), a global partnership fighting women’s cancers, have been working together to reduce the rate of female cancers among women who are co-infected with HIV.

Eight organizations have received grants that will continue to build knowledge about HIV and cancer, increase HIV/cervical/breast cancer screening and diagnosis efforts and strengthen the Foundation’s collaboration with PRRR. Programs will be implemented by Tanzania Youth Alliance; Medical Women Association of Tanzania; Mbeya HIV/AIDS Network, Tanzania; Tanzania Marketing and Communications; Mathiwos Wondu-YeEthiopia Cancer Society, Ethiopia; Doctors With Africa CUAMM, Tanzania; Sex Workers Education and Advocacy Task Force, South Africa; and Forum for African Women Educationalists Swaziland Chapter.

HIV and Tuberculosis
In countries with high levels of HIV, such as those in sub-Saharan Africa, about 80% of people with TB also have HIV. Globally, TB is among the deadliest diseases and a leading killer of people living with HIV. Since it was launched in 1999, the Foundation’s Secure the Future initiative has been committed to helping patients with TB who also have HIV. For the past three years, the Foundation has been collaborating with the World Health Organization’s (WHO) Global TB Program on ENGAGE-TB, a program to strengthen community-based care for patients who have TB and for those co-infected with HIV.

Grants to partners who are building capacity within communities for integrated HIV/TB screening, diagnosis and treatment will be implemented by Consortium of Christian Relief & Development Association, Ethiopia; National University of Lesotho Consuls Unit; and Grassroots Poverty Alleviation Program, Kenya.

About the Bristol-Myers Squibb Foundation
The mission of the Bristol-Myers Squibb Foundation is to help reduce health disparities by strengthening community-based health care worker capacity, integrating medical care and community-based supportive services, and mobilizing communities in the fight against disease.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Pfizer receives FDA approval for SUTENT® (sunitini…

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

Efficacy and safety maintained in patients who swi…

Boehringer Ingelheim today announced one-year data from VOLTAIRE®-RA, a pivotal Phase III clinical trial comparing Cyltezo® (adalimumab-adbm) and reference product Humira...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]